Galafold 123 MG
Ended Awarded Last action
- Contract number
- 36C24526N0379
- Awardee
-
Amicus Therapeutics US, LLC UEI KLJFGENKMD89
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $22,840
Award facts
- Contract value 100% obligated
- $22,839.61 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Philadelphia, PA 19104, USA
Award details come from SAM.gov/FPDS.
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 5 (Mid-Atlantic region), awarded a delivery order valued at $22,839.61 to Amicus Therapeutics US, LLC for the supply of Galafold 123 mg, an FDA-approved enzyme replacement therapy used to treat Fabry disease in veterans. This firm fixed-price delivery order, awarded on March 4, 2026, with an ultimate completion date of March 6, 2026, represents a child order under the parent Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract (36F79724D0185) valued at $13.0 million and effective through August 31, 2029. The award carries no set-aside designation and specifies performance at a VA facility in Philadelphia, Pennsylvania.
Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc., specializes in treatments for rare genetic diseases and has emerged as the primary supplier of Galafold to the Veterans Health Administration across multiple geographic regions. The company has fulfilled over 150 delivery orders since March 2021 under the FSS-61-IB schedule, with individual order values ranging from approximately $18,500 to $284,600, demonstrating consistent demand for this critical rare disease medication across multiple Veterans Integrated Service Networks. As the sole prime contractor on these orders with no subcontractor involvement, Amicus Therapeutics maintains complete control over the supply chain for this specialized pharmaceutical product essential to veteran care.
Quick answers
Who was awarded contract 36C24526N0379?
36C24526N0379 was awarded to Amicus Therapeutics US, LLC by Veterans Integrated Service Network 5 (Veterans Health Administration) on March 4, 2026.
How much is contract 36C24526N0379 worth?
The government has obligated $22,840 on 36C24526N0379.
Is contract 36C24526N0379 an order under another contract?
Yes. 36C24526N0379 is a delivery order under 36F79724D0185, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0379 competed?
The extent of competition for 36C24526N0379 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award